Breaking News Instant updates and real-time market news.

CLLS

Cellectis

$16.86

-0.76 (-4.31%)

, FMS

Fresenius Medical

$38.96

-0.45 (-1.14%)

07:43
12/01/16
12/01
07:43
12/01/16
07:43

Deutsche Bank to hold a conference

Pharmaceutical & Healthcare Corporate Day is being held in London, England on December 1.

CLLS

Cellectis

$16.86

-0.76 (-4.31%)

FMS

Fresenius Medical

$38.96

-0.45 (-1.14%)

AZN

AstraZeneca

$26.14

-0.57 (-2.13%)

NVS

Novartis

$68.76

-0.2 (-0.29%)

NVO

Novo Nordisk

$33.60

0.88 (2.69%)

RHHBY

Roche

$27.76

-0.05 (-0.18%)

  • 01

    Dec

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

  • 07

    Dec

  • 16

    Feb

CLLS Cellectis
$16.86

-0.76 (-4.31%)

11/23/16
PIPR
11/23/16
NO CHANGE
PIPR
Piper says CAR-T researchers must heed risks highlighted by Juno news
Piper Jaffray analyst Joshua Schimmer said the CAR-T field has "taken another step back" after Juno Therapeutics (JUNO) put a hold on its JCAR015 trial again due to fatal cerebral edema and cautioned companies exploring these therapies to be mindful of "unnecessarily aggressive development and under-appreciation of the potent and possibly highly toxic nature" of the approach. However, Schimmer expressed his confidence that companies he covers in the CAR-T space - namely bluebird bio (BLUE), Cellectis (CLLS), Celgene (CELG), Bellicum Pharmaceuticals (BLCM), Lion Biotechnologies (LBIO) and NantKwest (NK) - will "respect the power of these platforms and remember patients' lives are more important than stock prices."
04/05/16
LTCO
04/05/16
INITIATION
Target $45
LTCO
Buy
Cellectis initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Cellectis with a Buy rating and $45 price target.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
10/27/16
LTCO
10/27/16
NO CHANGE
Target $45
LTCO
Buy
Cellectis recent selloff unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li says the recent pullback in shares of Cellectis is unwarranted. The UCART19 Phase 1 trial is dosing patients on schedule, which is a positive sign for the outcome readout of the trial, Li tells investors in a research note. The analyst recommends buying the shares on the pullback and keeps a Buy rating on the name with a $45 price target.
FMS Fresenius Medical
$38.96

-0.45 (-1.14%)

09/06/16
SBSH
09/06/16
INITIATION
Target $71
SBSH
Neutral
DaVita initiated with a Neutral at Citi
Citi analyst Patrick Wood started DaVita Healthcare Partners (DVA) with a Neutral rating and $71 price target. The analyst sees limited upside to consensus estimates and prefers Fresenius Medical Care (FMS) at current share levels.
09/06/16
SBSH
09/06/16
INITIATION
SBSH
Buy
Fresenius Medical initiated with a Buy at Citi
Price target EUR 98.
10/13/16
RHCO
10/13/16
NO CHANGE
RHCO
Price targets cut on dialysis stocks at SunTrust
SunTrust analyst David MacDonald lowered his price targets on dialysis stocks, citing CMS' recent request for information and resulting payor risk and lower assumed multiples. The analyst cut his price target on American Renal Associates (ARA) to $24 from $34, on DaVita (DVA) to $66 from $80 and on Fresenius Medical (FMS) to $48 from $54. He maintains Buy ratings on American Renal and Fresenius but said he does not expect the stocks to rise significantly until the CMS matter is resolved. MacDonald keeps a Hold rating on DaVita.
07/08/16
JEFF
07/08/16
UPGRADE
JEFF
Hold
Fresenius Medical upgraded to Hold from Underperform at Jefferies
Jefferies analyst Chris Cooper upgraded Fresenius Medical to Hold with a EUR 81 price target.
AZN AstraZeneca
$26.14

-0.57 (-2.13%)

10/26/16
PIPR
10/26/16
NO CHANGE
PIPR
Neutral
Piper still uncertain on Clovis position after AstraZeneca data
AstraZeneca's (AZN) Phase III study of Lynparza in ovarian cancer "substantially improved" progression-free survival over what was seen in study 19, suggesting a profile at least similar to TESARO's (TSRO) niraparib, Piper Jaffray analyst Steven Breazzano tells investors in a research note. The new data confirm that the various PARP inhibitors are more similar than different, which bodes well for Clovis Oncology's (CLVS) own maintenance study, the analyst contends. Breazzano, however, remains the sidelines with respect to Clovis shares given the "increasingly competitive dynamic" in ovarian cancer and uncertainty in the company's position in the important maintenance setting. The analyst keeps a Neutral rating on Clovis.
11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/28/16
SBSH
11/28/16
DOWNGRADE
Target $60
SBSH
Neutral
Citi analyst 'perturbed,' downgrades AbbVie to Neutral
Citi analyst Andrew Baum earlier today downgraded AbbVie (ABBV) to Neutral from Buy and lowered his price target for the shares to $60 from $65. The biopharmaceutical company is trading down 2%, or 99c, to $59.52. The risk to post 2017 consensus estimates for Humira has "increased on almost all fronts," Baum tells investors in a research note. The analyst sees increased patent risk and competition from biosimilar Enbrel in Europe. He also believes AstraZeneca (AZN) and Acerta's acalabrutinib "looks like a better mousetrap" than AbbVie's Imbruvica. Baum is also "perturbed" by AbbVie management's recent "rich" acquisition of Stemcentrx. He prefers shares of Eli Lilly (LLY) and Bristol-Myers (BMY) to AbbVie.
10/20/16
JANY
10/20/16
NO CHANGE
Target $1.5
JANY
Neutral
Cerulean cash infusion gives chance to execute on programs, says Janney Capital
Janney Capital analyst Debjit Chattopadhyay said Cerulean's (CERU) collaboration with Novartis (NVS), which comes with a "modest" $5M upfront payment, and its $20M ATM facility with Aspire Capital, while "not ideal," gives management a chance to execute on three of its ongoing programs, the most important of which is the dose escalation study with Olaparib with partner AstraZeneca (AZN) that should have preliminary data in 2Q17. The analyst raised his fair value estimate on Cerulean to $1.50 from $1.00 and keeps a Neutral rating on the stock.
NVS Novartis
$68.76

-0.2 (-0.29%)

11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.
10/26/16
LEER
10/26/16
NO CHANGE
Target $80
LEER
Market Perform
Novartis price target lowered to $80 from $89 at Leerink
Leerink analyst Seamus Fernandez lowered his price target for Novartis to $80 from $89 after a "disappointing" Q3 performance despite bottom-line beat. The analyst reiterates a Market Perform rating on the shares.
11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
NVO Novo Nordisk
$33.60

0.88 (2.69%)

09/23/16
PIPR
09/23/16
INITIATION
PIPR
Neutral
Novo Nordisk initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Richard Purkiss started Novo Nordisk with a Neutral rating and DKK 320 price target.
10/28/16
BOFA
10/28/16
DOWNGRADE
BOFA
Underperform
Novo Nordisk downgraded to Underperform from Neutral at BofA/Merrill
10/31/16
SBSH
10/31/16
DOWNGRADE
SBSH
Neutral
Novo Nordisk downgraded to Neutral from Buy at Citi
Citi analyst Peter Verdult downgraded Novo Nordisk to Neutral citing the ongoing net pricing declines across the company's diabetes portfolio as well as expectations for margin erosion at Biopharmaceuticals due to NovoSeven/Norditropin pressures. The analyst cut his price target for the shares to DKK 260 from DKK 400.
09/13/16
EXAN
09/13/16
UPGRADE
EXAN
Outperform
Novo Nordisk upgraded to Outperform from Neutral at Exane BNP Paribas
RHHBY Roche
$27.76

-0.05 (-0.18%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.

TODAY'S FREE FLY STORIES

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$108.14

-1.86 (-1.69%)

17:04
12/02/16
12/02
17:04
12/02/16
17:04
Syndicate
Breaking Syndicate news story on Diamondback Energy »

Diamondback Energy files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIR

Osiris

$5.68

0.06 (1.07%)

17:02
12/02/16
12/02
17:02
12/02/16
17:02
Hot Stocks
Osiris: Nasdaq grants company's request for additional time »

Osiris Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STOR

STORE Capital

$24.45

0.52 (2.17%)

17:00
12/02/16
12/02
17:00
12/02/16
17:00
Hot Stocks
STORE Capital director Donovan acquires 4,350 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CARB

Carbonite

$17.95

0.25 (1.41%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
Breaking Hot Stocks news story on Carbonite »

Crosslink lowers stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIB

CGI Group

$47.11

0.16 (0.34%)

16:48
12/02/16
12/02
16:48
12/02/16
16:48
Hot Stocks
CGI Group announces specific share repurchase program »

CGI Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.